181 related articles for article (PubMed ID: 31456491)
1. Comparison of Prostaglandin Analog Treatment Patterns in Glaucoma and Ocular Hypertension.
Heo JH; Rascati KL; Wilson JP; Lawson KA; Richards KM; Nair R
J Manag Care Spec Pharm; 2019 Sep; 25(9):1001-1010. PubMed ID: 31456491
[TBL] [Abstract][Full Text] [Related]
2. Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study.
Reardon G; Schwartz GF; Mozaffari E
Clin Ther; 2003 Apr; 25(4):1172-85. PubMed ID: 12809964
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension.
Lin L; Zhao YJ; Chew PT; Sng CC; Wong HT; Yip LW; Wu TS; Bautista D; Teng M; Khoo AL; Lim BP
Ann Pharmacother; 2014 Dec; 48(12):1585-93. PubMed ID: 25184309
[TBL] [Abstract][Full Text] [Related]
4. Persistence on prostaglandin ocular hypotensive therapy: an assessment using medication possession and days covered on therapy.
Reardon G; Schwartz GF; Kotak S
BMC Ophthalmol; 2010 Mar; 10():5. PubMed ID: 20196848
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of bimatoprost versus travoprost in patients previously on latanoprost: a 3-month, randomised, masked-evaluator, multicentre study.
Kammer JA; Katzman B; Ackerman SL; Hollander DA
Br J Ophthalmol; 2010 Jan; 94(1):74-9. PubMed ID: 19726422
[TBL] [Abstract][Full Text] [Related]
6. First-year treatment patterns among new initiators of topical prostaglandin analogs.
Schmier JK; Covert DW; Robin AL
Curr Med Res Opin; 2009 Apr; 25(4):851-8. PubMed ID: 19231912
[TBL] [Abstract][Full Text] [Related]
7. Hyperemia-associated costs of medication changes in glaucoma patients treated initially with prostaglandin analogs.
Schwartz GF; Tan J; Kotak S
J Ocul Pharmacol Ther; 2009 Dec; 25(6):555-61. PubMed ID: 20028264
[TBL] [Abstract][Full Text] [Related]
8. Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost.
Covert D; Robin AL
Curr Med Res Opin; 2006 May; 22(5):971-6. PubMed ID: 16709319
[TBL] [Abstract][Full Text] [Related]
9. Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials.
Honrubia F; García-Sánchez J; Polo V; de la Casa JM; Soto J
Br J Ophthalmol; 2009 Mar; 93(3):316-21. PubMed ID: 19019922
[TBL] [Abstract][Full Text] [Related]
10. Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment.
Oddone F; Kirwan J; Lopez-Lopez F; Zimina M; Fassari C; Holló G;
Adv Ther; 2022 Aug; 39(8):3501-3521. PubMed ID: 35524840
[TBL] [Abstract][Full Text] [Related]
11. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study.
Parrish RK; Palmberg P; Sheu WP;
Am J Ophthalmol; 2003 May; 135(5):688-703. PubMed ID: 12719078
[TBL] [Abstract][Full Text] [Related]
12. Objective ocular surface tolerance in patients with glaucoma treated with topical preserved or unpreserved prostaglandin analogues.
El Ameen A; Vandermeer G; Khanna RK; Pisella PJ
Eur J Ophthalmol; 2019 Nov; 29(6):645-653. PubMed ID: 30301370
[TBL] [Abstract][Full Text] [Related]
13. Ocular surface tolerability of prostaglandin analogs and prostamides in patients with glaucoma or ocular hypertension.
Crichton AC; Vold S; Williams JM; Hollander DA
Adv Ther; 2013 Mar; 30(3):260-70. PubMed ID: 23475405
[TBL] [Abstract][Full Text] [Related]
14. Physicians' treatment decisions, patient persistence, and interruptions in the continuous use of prostaglandin therapy in glaucoma.
Hahn SR; Kotak S; Tan J; Kim E
Curr Med Res Opin; 2010 Apr; 26(4):957-63. PubMed ID: 20163296
[TBL] [Abstract][Full Text] [Related]
15. Prospective randomized clinical trial on the effects of latanoprost, travoprost and bimatoprost on latanoprost non-responders.
Blondeau P; Hamid M; Ghalie Z
J Fr Ophtalmol; 2019 Oct; 42(8):894-899. PubMed ID: 31164290
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of prostaglandin analogues in primary open-angle glaucoma or ocular hypertension patients: A meta-analysis.
Tang W; Zhang F; Liu K; Duan X
Medicine (Baltimore); 2019 Jul; 98(30):e16597. PubMed ID: 31348303
[TBL] [Abstract][Full Text] [Related]
17. Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension.
Whitson JT; Trattler WB; Matossian C; Williams J; Hollander DA
J Ocul Pharmacol Ther; 2010 Jun; 26(3):287-92. PubMed ID: 20578283
[TBL] [Abstract][Full Text] [Related]
18. Additivity of bimatoprost or travoprost to latanoprost in glaucomatous monkey eyes.
Gagliuso DJ; Wang RF; Mittag TW; Podos SM
Arch Ophthalmol; 2004 Sep; 122(9):1342-7. PubMed ID: 15364714
[TBL] [Abstract][Full Text] [Related]
19. Factors Related to Prostaglandin-Associated Periorbitopathy in Glaucoma Patients.
Patradul C; Tantisevi V; Manassakorn A
Asia Pac J Ophthalmol (Phila); 2017; 6(3):238-242. PubMed ID: 28379653
[TBL] [Abstract][Full Text] [Related]
20. Refill rates and budget impact of glaucoma lipid therapy: a retrospective database analysis.
Walt JG; Wilensky JT; Fiscella R; Chiang TH; Guckian A
Clin Drug Investig; 2007; 27(12):819-25. PubMed ID: 18020539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
